Loading...

Kreshnik Zejnullahu, MD

Title(s)Attending Physician, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue
San Francisco CA 94117
Phone--
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa437. Gandelman JS, Kim EY, Grzegorczyk AM, Zejnullahu K, Edson RS. PMID: 33094121.
      View in: PubMed   Mentions:
    2. Off Trail, On Track: an Exercise in Clinical Reasoning. J Gen Intern Med. 2019 10; 34(10):2282-2287. Zejnullahu K, Santhosh L, Mourad M, Connor DM. PMID: 31270781.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    4. Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e23055-e23055. Archana Anantharaman, Terence W. Friedlander, Christopher J. Welty, Kreshnik Zejnullahu, Jeffrey Hough, Matthew Edwards, Adam Jendrisak, Jerry Lee, Stephanie Greene, Priscilla Ontiveros, Ryon Graf, Angel Rodriguez, Mahipal Suraneni, Yipeng Wang, Mark Andrew Landers, Matthew R. Cooperberg, Peter Carroll, Ryan Vance Dittamore, Pamela Paris. .
      View in: Publisher Site   Mentions:
    5. Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 Feb 20; 35(6_suppl):110-110. Terence W. Friedlander, Archana Anantharaman, Christopher Welty, Kreshnik Zejnullahu, Jeffrey Hough, Matthew Edwards, Adam Jendrisak, Jerry Lee, Stephanie Greene, Priscilla Ontiveros, Ryon Graf, Angel Rodriguez, Mahipal Suraneni, Yipeng Wang, Mark Andrew Landers, Matthew R. Cooperberg, Peter Carroll, Ryan Vance Dittamore, Pamela Paris. .
      View in: Publisher Site   Mentions:
    6. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 08; 34(8):368-74. PMID: 26944450.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears. J Gen Intern Med. 2016 07; 31(7):812-3. PMID: 26892322.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife. 2015 Jun 05; 4:e06907. PMID: 26047463.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    9. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013 Jan 15; 73(2):834-43. PMID: 23172312.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    10. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19408-13. PMID: 23129625.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCells
    11. OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. European Journal of Cancer. 2011 Oct 1; 47:s10. K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, J. Engelman, M. Varella-Garcia, K. Nakagawa, P. Jänne. .
      View in: Publisher Site   Mentions:
    12. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011 Sep 07; 3(99):99ra86. PMID: 21900593.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansAnimalsCells
    13. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010 Apr 22; 29(16):2346-56. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. PMID: 20118985.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCells
    14. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. PMID: 20129249.
      View in: PubMed   Mentions: 391     Fields:    Translation:HumansAnimalsCells
    15. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA. PMID: 18980991.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    16. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 01; 14(13):4275-83. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. PMID: 18594010.
      View in: PubMed   Mentions: 308     Fields:    Translation:HumansCells
    17. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PMID: 18089823.
      View in: PubMed   Mentions: 222     Fields:    Translation:HumansAnimalsCells
    18. C7-07: Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s382. Kimio Yonesaka, Kreshnik Zejnullahu, Alison J. Homes, Bruce E. Johnson, Pasi A. Janne. .
      View in: Publisher Site   Mentions:
    19. D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s396. Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen, Rogers M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Johnson E. Bruce, Lewis C. Cantley, Pasi A. Jänne. .
      View in: Publisher Site   Mentions:
    20. C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s361. Joon Oh Park, Feng Zhao, Kreshnik Zejnullahu, Emmanuel Normant, Jeffrey A. Engelman, Bruce E. Johnson, Pasi A. Jänne. .
      View in: Publisher Site   Mentions:
    21. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. PMID: 17463250.
      View in: PubMed   Mentions: 1657     Fields:    Translation:HumansAnimalsCells
    22. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. PMID: 16906227.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansAnimalsCells
    Kreshnik's Networks
    Concepts (114)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑